[{"data":1,"prerenderedAt":211},["ShallowReactive",2],{"drug-aztreonam":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":107,"warnings":117,"renal":124,"monitoring":125,"interactions":126,"review":127,"examples":130,"atc":145,"iran":147,"links":154,"populations":172,"usApproval":206},"aztreonam",1,{"fa":7,"en":8},"آزترئونام","Aztreonam","anti-infectives",{"fa":11,"en":12},"مونوباکتام","Monobactam",[14],{"name":15,"market":16},"Azactam","US",[18,7,19],"azactam","آزترونام",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"vial-1g","powder-for-injection","iv","1 g vial",{"amount":27,"unit":28,"perUnit":29},1000,"mg","vial",[16],[32],{"source":33,"section":34},"fda-azactam","How Supplied",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"vial-2g","2 g vial",{"amount":39,"unit":28,"perUnit":29},2000,[16],[42],{"source":33,"section":34},[44,61,86],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":58},"uti","urinary-tract-infection",{"fa":48,"en":49},"UTI — بزرگسال ۵۰۰ mg یا ۱ g هر ۸ تا ۱۲ ساعت","UTI — adult 500 mg or 1 g every 8–12 h",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":56,"perDoseMax":27,"dosesPerDay":57},500,2,[59],{"source":33,"section":60},"Dosage and Administration",{"id":62,"disease":63,"label":64,"population":67,"type":54,"unit":28,"dose":69,"refs":71,"limits":73,"notes":77},"severe","sepsis",{"fa":65,"en":66},"عفونت شدید یا تهدیدکننده حیات (پسودوموناس) — بزرگسال ۲ g هر ۶ تا ۸ ساعت","Severe or life-threatening infection (Pseudomonas) — adult 2 g every 6–8 h",{"minAge":68},{"value":52,"unit":53},{"perDose":39,"dosesPerDay":70},3,[72],{"source":33,"section":60},{"maxPerDay":74,"refs":75},8000,[76],{"source":33,"section":60},[78],{"text":79,"refs":82},{"fa":80,"en":81},"عفونت سیستمیک متوسط: ۱ یا ۲ g هر ۸ تا ۱۲ ساعت. حداکثر ۸ g\u002Fروز. حساسیت متقاطع با سایر بتالاکتام‌ها نادر است.","Moderately severe systemic: 1 or 2 g every 8–12 h. Max 8 g\u002Fday. Cross-reactivity with other beta-lactams is rare.",[83,84],{"source":33,"section":60},{"source":33,"section":85},"Warnings",{"id":87,"disease":63,"label":88,"population":91,"type":97,"unit":28,"dose":98,"refs":101,"limits":103},"child",{"fa":89,"en":90},"کودک ۹ ماه تا ۱۶ سال — ۳۰ mg\u002Fkg هر ۶ تا ۸ ساعت (حداکثر ۱۲۰ mg\u002Fkg\u002Fروز)","Children 9 months–16 y — 30 mg\u002Fkg every 6–8 h (max 120 mg\u002Fkg\u002Fday)",{"minAge":92,"maxAge":95},{"value":93,"unit":94},9,"month",{"value":96,"unit":53},17,"weightBased",{"perKgPerDose":99,"intervalHours":100},30,8,[102],{"source":33,"section":60},{"maxPerKgPerDay":104,"refs":105},120,[106],{"source":33,"section":60},[108],{"id":109,"severity":110,"text":111,"refs":114},"hyper","block",{"fa":112,"en":113},"حساسیت به آزترئونام.","Hypersensitivity to aztreonam.",[115],{"source":33,"section":116},"Contraindications",[118],{"text":119,"refs":122},{"fa":120,"en":121},"واکنش آلرژیک جدی؛ اسهال مرتبط با کلستریدیوئیدس دیفیسیل.","Serious hypersensitivity; Clostridioides difficile-associated diarrhoea.",[123],{"source":33,"section":85},[],[],[],{"status":128,"reviewer":129,"date":129},"unverified",null,[131,136,139],{"regimen":45,"formulation":22,"input":132,"expect":135},{"ageYears":133,"weightKg":134},50,70,{"perDose":56,"upperPerDose":27},{"regimen":62,"formulation":36,"input":137,"expect":138},{"ageYears":133,"weightKg":134},{"perDose":39,"dosesPerDay":70},{"regimen":87,"formulation":22,"input":140,"expect":143},{"ageYears":141,"weightKg":142},6,20,{"perDose":144},600,[146],"J01DF01",{"status":148,"refs":149},"not-found",[150],{"source":151,"section":152,"url":153},"darooyab-generic","G-288\u002FAztreonam","https:\u002F\u002Fwww.darooyab.ir\u002FG-288\u002FAztreonam",[155,159,163,167,170],{"kind":156,"url":157,"label":158},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=050580","NDA050580",{"kind":160,"url":161,"label":162},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2","FDA Azactam",{"kind":164,"url":165,"label":166},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa687010.html","Aztreonam Injection",{"kind":168,"url":169,"label":146},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01DF01",{"kind":171,"url":153,"label":8},"darooyab",{"pregnancy":173,"lactation":182,"pediatric":190,"geriatric":198},{"level":174,"text":175,"quote":178,"refs":179},"caution",{"fa":176,"en":177},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Because animal reproduction studies are not always predictive of human response, aztreonam should be used during pregnancy only if clearly needed.",[180],{"source":33,"section":181},"Pregnancy",{"level":174,"text":183,"quote":186,"refs":187},{"fa":184,"en":185},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Aztreonam is excreted in human milk in concentrations that are less than 1% of concentrations determined in simultaneously obtained maternal serum; consideration should be given to temporary discontinuation of nursing and use of formula feedings.",[188],{"source":33,"section":189},"Nursing Mothers",{"level":174,"text":191,"quote":194,"refs":195},{"fa":192,"en":193},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of intravenous AZACTAM have been established in the age groups 9 months to 16 years.",[196],{"source":33,"section":197},"Pediatric Use",{"level":174,"text":199,"quote":202,"refs":203},{"fa":200,"en":201},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[204],{"source":33,"section":205},"Geriatric Use",{"kind":207,"refs":208,"id":158},"NDA",[209],{"source":33,"section":210},"SPL approval \u002F marketing category",1792191527758]